Relevant bibliographies by topics / Thiazolidinedione (TZD)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Thiazolidinedione (TZD)'

Author: Grafiati
Published: 4 June 2021
Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Thiazolidinedione (TZD).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Thiazolidinedione (TZD)"

1

Rahman, Safikur, Md Tabish Rehman, Gulam Rabbani, et al. "Insight of the Interaction between 2,4-thiazolidinedione and Human Serum Albumin: A Spectroscopic, Thermodynamic and Molecular Docking Study." International Journal of Molecular Sciences 20, no. 11 (2019): 2727. http://dx.doi.org/10.3390/ijms20112727.

Full text
Abstract:
Thiazolidinedione derivatives (TZDs) have attracted attention because of their pharmacological effects. For example, certain TZDs have been reported to ameliorate type II diabetes by binding and activating PPARs (peroxisome proliferator-activated receptors). Nonetheless, no information is available on the interaction between the heterocyclic 2, 4-thiazolidinedione (2,4-TZD) moiety and serum albumin, which could affect the pharmacokinetics and pharmacodynamics of TZDs. In this study, we investigated the binding of 2,4-TZD to human serum albumin (HSA). Intrinsic fluorescence spectroscopy reveale
APA, Harvard, Vancouver, ISO, and other styles
2

Ortmeyer, Heidi K., Noni L. Bodkin, Joseph Haney, Shinji Yoshioka, Hiroyoshi Horikoshi, and Barbara C. Hansen. "A Thiazolidinedione ImprovesIn VivoInsulin Action on Skeletal Muscle Glycogen Synthase in Insulin-Resistant Monkeys." International Journal of Experimental Diabetes Research 1, no. 3 (2000): 195–202. http://dx.doi.org/10.1155/edr.2000.195.

Full text
Abstract:
Thiazolidinediones (TZD) have been shown to have anti-diabetic effects including the ability to decrease fasting hyperglycemia and hyperinsulinemia, increase insulin-mediated glucose disposal rate (M) and decrease hepatic glucose production, but the mechanisms of action are not well established. To determine whether a TZD (R-102380, Sankyo Company Ltd., Tokyo, Japan) could improve insulin action on skeletal muscle glycogen synthase (GS), the rate-limiting enzyme in glycogen synthesis, 4 insulin-resistant obese monkeys were given I mg/kg/ day R-102380 p.o. for a 6-week period. Skeletal muscle G
APA, Harvard, Vancouver, ISO, and other styles
3

Chis, Irina C., Doina Baltaru, Simona Clichici, Ovidiu Oniga, Ileana Cojocaru, and Cristina Nastasa. "The Effects of a 5-Chromene-yl-thiazolidin-2,4-dione Derivative in Alleviating Oxidative Stress in Adjuvant-Induced Arthritis." Revista de Chimie 69, no. 9 (2018): 2361–65. http://dx.doi.org/10.37358/rc.18.9.6534.

Full text
Abstract:
Rheumatoid arthritis (RA) is a chronic inflammatory disease that reduces life quality and requires long-life therapy. Quercetin (Que) is a natural flavonoid with antioxidant and anti-inflammatory effects. (3-(2-(4-Chlorophenyl)-2-oxoethyl)-5-((6-methyl-4-oxo-4H-chromen-3-yl)methylene) thiazolidine-2,4-dione (TZD) is a thiazolidinedione derivative synthesized in our laboratory. This study was designed to investigate the antioxidant effects of the Que and TZD derivative administration in adjuvant-induced arthritic (AIA) rats. AIA was induced in Wistar rats by the intraplantar injection of Freund
APA, Harvard, Vancouver, ISO, and other styles
4

Kim, Won Jun, Jung Hyun Noh, Kyungdo Han, and Cheol-Young Park. "The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study." Journal of Alzheimer's Disease 81, no. 3 (2021): 1263–72. http://dx.doi.org/10.3233/jad-201535.

Full text
Abstract:
Background: There are few reports that evaluated the association between various types of dementia and dual oral therapy with antihyperglycemic medication. Objective: The goal of this study was to investigate the association between treatment of dual antihyperglycemic medication and dementia subclass in type 2 diabetes mellitus using the Korean National Health Insurance System. Methods: This study included 701,193 individuals with diabetes prescribed dual oral therapy between 2009 and 2012 from the Korean National Health Insurance Service Database, which were tracked until 2017. All-cause, Alz
APA, Harvard, Vancouver, ISO, and other styles
5

Corigliano, Domenica M., Riyaz Syed, Sebastiano Messineo, et al. "Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators." PeerJ 6 (August 8, 2018): e5386. http://dx.doi.org/10.7717/peerj.5386.

Full text
Abstract:
Background Thiazolidinediones (TZDs), also called glitazones, are five-membered carbon ring molecules commonly used for the management of insulin resistance and type 2 diabetes. Recently, many prospective studies have also documented the impact of these compounds as anti-proliferative agents, though several negative side effects such as hepatotoxicity, water retention and cardiac issues have been reported. In this work, we synthesized twenty-six new TZD analogues where the thiazolidinone moiety is directly connected to an N-heterocyclic ring in order to lower their toxic effects. Methods By ad
APA, Harvard, Vancouver, ISO, and other styles
6

van de Vyver, M., E. Andrag, I. L. Cockburn, and W. F. Ferris. "Thiazolidinedione-induced lipid droplet formation during osteogenic differentiation." Journal of Endocrinology 223, no. 2 (2014): 119–32. http://dx.doi.org/10.1530/joe-14-0425.

Full text
Abstract:
Chronic administration of the insulin-sensitising drugs, thiazolidinediones (TZDs), results in low bone mineral density and ‘fatty bones’. This is thought to be due, at least in part, to aberrant differentiation of progenitor mesenchymal stem cells (MSCs) away from osteogenesis towards adipogenesis. This study directly compared the effects of rosiglitazone, pioglitazone, and netoglitazone treatment on osteogenesis and adipogenesis in MSCs derived from subcutaneous (SC) or visceral (PV) white adipose tissue. MSCs were isolated from adipose tissue depots of male Wistar rats and characterised usi
APA, Harvard, Vancouver, ISO, and other styles
7

Rosa, Fernanda, Misagh Moridi, Johan S. Osorio, et al. "2,4-Thiazolidinedione in Well-Fed Lactating Dairy Goats: II. Response to Intra-Mammary Infection." Veterinary Sciences 6, no. 2 (2019): 52. http://dx.doi.org/10.3390/vetsci6020052.

Full text
Abstract:
In a prior experiment, treatment of goats with the putative PPARγ agonist 2,4-thiazolidinedione (2,4-TZD) ameliorated the response to intramammary infection without evidence of PPARγ activation. The lack of PPARγ activation was possibly due to deficiency of vitamin A and/or a poor body condition of the animals. Therefore, the present study hypothesized that activation of PPARγ by 2,4-TZD in goats supplemented with adequate amounts of vitamin A can improve the response to sub-clinical mastitis. Lactating goats receiving a diet that met National Research Council requirements, including vitamin A
APA, Harvard, Vancouver, ISO, and other styles
8

Rosa, Fernanda, Johan S. Osorio, Erminio Trevisi, Francisco Yanqui-Rivera, Charles T. Estill, and Massimo Bionaz. "2,4-Thiazolidinedione Treatment Improves the Innate Immune Response in Dairy Goats with Induced Subclinical Mastitis." PPAR Research 2017 (2017): 1–22. http://dx.doi.org/10.1155/2017/7097450.

Full text
Abstract:
Mastitis is a major disease in dairy cows resulting in significant economic losses. In vitro works suggest that ruminants peroxisome proliferator-activated receptor gamma (PPARγ) can aid in improving the response to mastitis and can control milk fat synthesis. The objectives of the present experiment were to test if treatment with the putative PPARγ agonist 2,4-thiazolidinedione (TZD) improves (1) the response to subclinical mastitis and (2) milk fat production. Lactating goats received daily injections of 8 mg/kg BW of TZD or saline for 3 weeks. After one week of TZD injection, half of the go
APA, Harvard, Vancouver, ISO, and other styles
9

Govindarajan, R., E. R. Siegel, D. L. Simmons, and N. P. Lang. "Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of head and neck (SCCHN)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 1511. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1511.

Full text
Abstract:
1511 Background: Peroxisome proliferator-activated receptor γ (PPARγ), a nucleic acid receptor, heterodimerizes with retinoic acid X receptor (RXR). Ligand activation of RXR leads to decreased proliferation of SCCHN cell lines. TZDs (syn: glitazones), used to treat diabetes mellitus (DM), are ligands for the RXR:PPARγ heterodimer. A retrospective study of diabetics attending the Veterans Affairs (VA) health care system was undertaken to assess the association between TZD exposure and the risk of developing SCCHN. Methods: Data were obtained from the electronic patient database VISN 16 (coverin
APA, Harvard, Vancouver, ISO, and other styles
10

Klopper, Joshua P., Vibha Sharma, Reid Bissonnette та Bryan R. Haugen. "Combination PPARγand RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2". PPAR Research 2010 (2010): 1–8. http://dx.doi.org/10.1155/2010/729876.

Full text
Abstract:
Nuclear hormone receptors, including RXR and PPARγ, represent novel therapeutic targets in melanoma. We have previously shown that the DRO subline of the amelanotic melanoma A375 responds to rexinoid and thiazolidinedione (TZD) treatmentin vitroandin vivo. We performed microarray analysis of A375(DRO) after TZD and combination rexinoid/TZD treatment in which the calcium binding protein S100A2 had increased expression after rexinoid or TZD treatment and a synergistic increase to combination treatment. Increased S100A2 expression is dependent on an intact PPARγreceptor, but it is not sufficient
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Thiazolidinedione (TZD)"

1

Spaeth, Brianne, and Barbara Fontana. "A Cost-Effectiveness Analysis Comparing Glargine Versus Rosiglitazone or Pioglitazone for Patients Failing Metformin Plus a Sulfonylurea." The University of Arizona, 2008. http://hdl.handle.net/10150/624269.

Full text
Abstract:
Class of 2008 Abstract<br>Objectives: To determine the cost-effectiveness of adding a thiazolidinedione (TZD) versus insulin glargine (glargine) as a triple regimen for treatment of Type 2 diabetes mellitus for patients not controlled with metformin and a sulfonylurea. Methods: A decision analytic model was developed to compare the clinical outcomes and costs of triple therapy with either a TZD or glargine. Published literature was used to determine treatment efficacy and the frequency of clinically important adverse effects. Cost data were obtained from the 2007 Physician Fee Reference and N
APA, Harvard, Vancouver, ISO, and other styles
2

Fulgencio, Jean-Pierre. "Effets d'un biguanide et de deux thiazolidinediones sur le métabolisme du glucose et des acides gras dans des hepatocytes de rat : des flux métaboliques à l'expression de gènes." Paris 7, 2003. http://www.theses.fr/2003PA077047.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Thiazolidinedione (TZD)"

1

Bourdon, Allen K., Greg Villareal, George Perry, and Clyde F. Phelix. "Alzheimer's and Parkinson's Disease Novel Therapeutic Target." In Research Anthology on Diagnosing and Treating Neurocognitive Disorders. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-3441-0.ch021.

Full text
Abstract:
Thiazolidinedione (TZD) drugs (Takeda Pharmaceuticals and Metabolic Solutions Development Company) targeting inhibition of the mitochondrial pyruvate carrier (MPC) are currently being tested in clinical trials to prevent progression into mild cognitive impairment of Alzheimer's disease (AD) or in the pipeline to prevent neurodegeneration in Parkinson's disease (PD). These have Ki values in the µM range. This study was focused on identifying candidate drug precursors of the natural cinnamic acid products that might have good bioavailability in the nM ranges forming covalent thiol bonds with targets. In silico protein homology modeling and ligand docking has demonstrated that binding cysteine residues within the transport channel is a key part of the inhibitory mechanism. These are covalent thiohemiacetal bonds with the alpha-carbon, carboxylate group, off a phenol ring. Like the classic MPC inhibitors, these natural derivatives of hydroxycinnamic acid have a conjugated pi-system used to form thiol bonds with the cysteine residue via Michael addition.
APA, Harvard, Vancouver, ISO, and other styles
2

Seth, AK, DC Gajzer, P. Suwandhi, et al. "Thiazolidinediones (TZDs) Inhibit Bone Turnover." In The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego. Endocrine Society, 2010. http://dx.doi.org/10.1210/endo-meetings.2010.part2.p4.p2-184.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Thiazolidinedione (TZD)"

1

Synan, MJ, MD Burdick та RM Strieter. "Thiazolidinediones (TZDs) Inhibit the Expression of Pro-Angiogenic ELR+ CXC Chemokines in Non-Small Cell Lung Cancer (NSCLC) Cells Via a PPAR-γ Independent Mechanism." У American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Thiazolidinedione (TZD)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography